Echo Therapeutics, Inc., a company developing its needle-free Symphonyâ„¢ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Preludeâ„¢ SkinPrep System for transdermal drug delivery, today announced results for the period ended March 31, 2011. Â Echo’s Quarterly Report on Form 10-Q is available through Echo’s website at www.echotx.com.
“The culmination of significant milestones we accomplished during the first quarter, including the completion of $6.4M of financing and the appointments of John Garibotto and Ken Gary, have positioned us for a very exciting year,” commented Patrick T. Mooney, M.D., Chairman and Chief Executive Officer of Echo Therapeutics. “The significant additional capital and key hires will drive the commercial launch of Prelude and the final development of the Symphony system.”
